-
21.发明授权公开(公告)号：US07138488B2
公开(公告)日：2006-11-21
申请号：US10363209
申请日：2001-09-05
申请人： Nobutaka Fujii
发明人： Nobutaka Fujii
CPC分类号： C07K7/08 , A61K38/00 , C07K14/43509 , Y10S530/857
摘要： Polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like).
摘要翻译： A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7（I）的多肽或其盐（其中A1是氢或精氨酸，赖氨酸，鸟氨酸，瓜氨酸，丙氨酸的残基 氨基酸残基; A3，A4和A6分别是精氨酸，赖氨酸，鸟氨酸，瓜氨酸或丙氨酸的残基; A5是酪氨酸，苯丙氨酸，丙氨酸，萘丙氨酸或瓜氨酸的残基; A7是其羧基可以转化为酰氨基的赖氨酸或精氨酸残基; X是D-鸟氨酰基脯氨酸，脯氨酰-D-鸟氨酸，D-赖氨酰脯氨酸等的残基，条件是任何一个A1 ，A3，A4，A5，A6和A7是丙氨酸等的残基或X是瓜氨酸等）。
-
公开(公告)号：US5059679A
公开(公告)日：1991-10-22
申请号：US331292
申请日：1989-03-30
申请人： Haruaki Yajima , Nobutaka Fujii , Shinya Kiyama
发明人： Haruaki Yajima , Nobutaka Fujii , Shinya Kiyama
IPC分类号： C07K1/06 , C07K1/00 , C07K1/113 , C07K14/00 , C07K14/575 , C07K14/595
CPC分类号： C07K1/006 , C07K14/595 , Y02P20/55
摘要： The invention provides a method and reagent for the modification of polypeptides useful in experimental research in the area of genetic engineering starting from a polypeptide such as hCCK-33 in an unsulfated form which contains Tyr and Ser and/or Thr residues by first protecting the amino-groups in the starting polypeptide, masking the OH-groups in the Ser and/or Thr residues and selectively sulfating the OH-groups in the Tyr residues after deprotection.
摘要翻译： 本发明提供了一种用于修饰可用于基因工程领域的实验研究领域的多肽的方法和试剂，其以多肽例如hCCK-33（其含有Tyr和Ser和/或Thr残基的未硫酸化形式）首先保护氨基 - 起始多肽中的基团，掩蔽Ser和/或Thr残基中的OH-基团，并且在去保护后选择性硫酸化Tyr残基中的OH-基团。
-
公开(公告)号：US20130045977A1
公开(公告)日：2013-02-21
申请号：US13579843
申请日：2011-02-17
申请人： Hideaki Kakeya , Akira Hattori , Yasuaki Takasu , Nobutaka Fujii , Shinya Oishi , Soichi Kojima , Mitsuko Hara
发明人： Hideaki Kakeya , Akira Hattori , Yasuaki Takasu , Nobutaka Fujii , Shinya Oishi , Soichi Kojima , Mitsuko Hara
IPC分类号： A61K31/445 , C07D401/12 , A61P25/00 , C07D413/12 , A61K31/5377 , A61P35/00 , C07D211/32 , A61K31/4545
CPC分类号： C07D295/104 , C07D211/28 , C07D295/18 , C07D405/12
摘要： The present invention provides a compound represented by the following formula (I) or a physiologically acceptable salt thereof, and use thereof for the prophylaxis or treatment of TGF-β-related diseases: wherein Y is a hydrogen atom and the like; R2 is and the like; R3 is —NR8—R9— and the like; R4, R5, R6 and R7 are the same or different and each is a hydrogen atom and the like; and X is and the like.
摘要翻译： 本发明提供由下式（I）表示的化合物或其生理学上可接受的盐，及其用于预防或治疗TGF-β相关疾病的用途：其中Y为氢原子等; R2是等等; R3是-NR8-R9-等; R4，R5，R6和R7相同或不同，各自为氢原子等; X等。
-
公开(公告)号：US20110014649A1
公开(公告)日：2011-01-20
申请号：US12296805
申请日：2007-07-26
申请人： Hiroko Tsutsumi , Hiroki Ishida , Hiromoto Hisada , Makiko Mizumoto , Yoji Hata , Nobutaka Fujii , Masao Matsuoka , Eiichi Kodama , Shinya Oishi
发明人： Hiroko Tsutsumi , Hiroki Ishida , Hiromoto Hisada , Makiko Mizumoto , Yoji Hata , Nobutaka Fujii , Masao Matsuoka , Eiichi Kodama , Shinya Oishi
CPC分类号： C07K14/005 , A61K38/00 , C12N2740/15022 , C12N2740/16122
摘要： The present invention relates to the production of an N36-binding peptide at low cost and in a large quantity utilizing a microorganism. More specifically, the present invention relates to a method for producing an N36-binding peptide comprising introducing a recombinant vector into which a DNA molecule encoding an N36-binding peptide that binds to an N36 protein derived from a retrovirus that causes immunodeficiency in a mammal has been incorporated into E. coli as a host to produce a transformant.
摘要翻译： 本发明涉及以低成本和大量利用微生物生产N36结合肽。 更具体地说，本发明涉及一种N36-结合肽的制造方法，其特征在于，包括引入重组载体，其中编码与衍生自引起哺乳动物免疫缺陷的逆转录病毒的N36蛋白结合的N36结合肽的DNA分子 作为宿主掺入大肠杆菌以产生转化体。
-
公开(公告)号：US20100222256A1
公开(公告)日：2010-09-02
申请号：US12583746
申请日：2009-08-25
申请人： Nobutaka Fujii
发明人： Nobutaka Fujii
CPC分类号： C07K7/08 , A61K38/00 , C07K14/43509
摘要： The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like), and methods of using same in the treatment of HIV.
摘要翻译： 本发明提供了A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7（I）或其盐（其中A1是氢或精氨酸，赖氨酸， 鸟氨酸，瓜氨酸，丙氨酸等; A2是芳香族氨基酸残基; A3，A4和A6分别是精氨酸，赖氨酸，鸟氨酸，瓜氨酸或丙氨酸的残基; A5是酪氨酸，苯丙氨酸，丙氨酸， 萘基丙氨酸或瓜氨酸; A7是其羧基可以转化为酰氨基的赖氨酸或精氨酸残基; X是D-鸟氨酸 - 脯氨酸，脯氨酰-D-鸟氨酸，D-赖氨酰脯氨酸等的残基，条件是 A1，A3，A4，A5，A6和A7中的任一个是丙氨酸等的残基，或者X是瓜氨酸等），以及在治疗HIV中使用它们的方法。
-
公开(公告)号：US20100160241A1
公开(公告)日：2010-06-24
申请号：US12298200
申请日：2006-10-24
申请人： Nobutaka Fujii , Shinya Oishi , Kenji Tomita , Ayumu Niida
发明人： Nobutaka Fujii , Shinya Oishi , Kenji Tomita , Ayumu Niida
CPC分类号： C07K5/0808 , A61K38/00 , C07K7/06
摘要： The present invention provides a compound represented by the following formula (1); wherein R1 is an aryl group etc.; R2 is —CO—NH— etc.; R3 is a methyl group having an aromatic group or a cycloalkyl group; R4 is a hydrogen atom etc.; R5 is a methyl group having an aromatic group; and R6 is an amino group or an N-alkyl substituted amino group, having a low-molecular weight and a superior GPR54 agonist activity, and a pharmaceutical composition containing the compound.
摘要翻译： 本发明提供由下式（1）表示的化合物。 其中R1是芳基等; R2是-CO-NH-等; R3是具有芳基或环烷基的甲基; R4是氢原子等。 R5是具有芳基的甲基; 和R6是具有低分子量和优异的GPR54激动剂活性的氨基或N-烷基取代的氨基，以及含有该化合物的药物组合物。
-
27.发明授权公开(公告)号：US07595298B2
公开(公告)日：2009-09-29
申请号：US11497225
申请日：2006-08-01
申请人： Nobutaka Fujii
发明人： Nobutaka Fujii
IPC分类号： A61K38/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K14/00 , C07K16/00 , C07K17/00 , A61K39/12 , A61K39/21
CPC分类号： C07K7/08 , A61K38/00 , C07K14/43509 , Y10S530/857
摘要： The present invention relates to a polypeptide represented by the formula: A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7 (I) (wherein A1 represents a hydrogen atom or an arginine, lysine, ornithine, citrulline, alanine residue, etc.; A2 represents an aromatic amino acid residue; A3, A4 and A6 represent an arginine, lysine, ornithine, citrulline or alanine residue, A5 represents a tyrosine, phenylalanine, alanine, naphthylalanine or citrulline residue; A7 represents a lysine or arginine residue in which a carboxyl group may be amidated; X represents a D-ornithyl-proline, prolyl-D-ornithine, D-lysyl-proline residue, etc.; provided that either of A1, A3, A4, A5, A6 and A7 is an alanine residue, etc., or X is citrulline, etc.) or a salt thereof.
摘要翻译： 本发明涉及由下式表示的多肽：<？in-line-formula description =“In-line formula”end =“lead”？> A1-Arg-A2-Cys-Tyr-A3-A4-X- A5-A6-Cit-Cys-A7（I）<？在线公式描述=“在线式”末端=“尾”→（其中A1表示氢原子或精氨酸，赖氨酸，鸟氨酸，瓜氨酸 ，丙氨酸残基等; A2表示芳香族氨基酸残基; A3，A4和A6表示精氨酸，赖氨酸，鸟氨酸，瓜氨酸或丙氨酸残基，A5表示酪氨酸，苯丙氨酸，丙氨酸，萘丙氨酸或瓜氨酸残基; A7表示 赖氨酸或精氨酸残基，其中羧基可以被酰胺化; X表示D-鸟氨酸 - 脯氨酸，脯氨酰-D-鸟氨酸，D-赖氨酰 - 脯氨酸残基等;条件是A1，A3，A4，A5， A6和A7是丙氨酸残基等，或X是瓜氨酸等）或其盐。
-
28.发明申请公开(公告)号：US20060264605A1
公开(公告)日：2006-11-23
申请号：US11497225
申请日：2006-08-01
申请人： Nobutaka Fujii
发明人： Nobutaka Fujii
IPC分类号： A61K39/12 , C07K14/00 , C07K16/00 , A61K38/00 , C07K17/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00
CPC分类号： C07K7/08 , A61K38/00 , C07K14/43509 , Y10S530/857
摘要： The present invention relates to a polypeptide represented by the formula: A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7 (I) (wherein A1 represents a hydrogen atom or an arginine, lysine, ornithine, citrulline, alanine residue, etc.; A2 represents an aromatic amino acid residue; A3, A4 and A6 represent an arginine, lysine, ornithine, citrulline or alanine residue, A5 represents a tyrosine, phenylalanine, alanine, naphthylalanine or citrulline residue; A7 represents a lysine or arginine residue in which a carboxyl group may be amidated; X represents a D-ornithyl-proline, prolyl-D-ornithine, D-lysyl-proline residue, etc.; provided that either of A1, A3, A4, A5, A6 and A7 is an alanine residue, etc., or X is citrulline, etc.) or a salt thereof.
摘要翻译： 本发明涉及由下式表示的多肽：<？in-line-formula description =“In-line formula”end =“lead”？> A1-Arg-A2-Cys-Tyr-A3-A4-X- A5-A6-Cit-Cys-A7（I）<？在线公式描述=“在线式”末端=“尾”→（其中A1表示氢原子或精氨酸，赖氨酸，鸟氨酸，瓜氨酸 ，丙氨酸残基等; A2表示芳香族氨基酸残基; A3，A4和A6表示精氨酸，赖氨酸，鸟氨酸，瓜氨酸或丙氨酸残基，A5表示酪氨酸，苯丙氨酸，丙氨酸，萘丙氨酸或瓜氨酸残基; A7表示 赖氨酸或精氨酸残基，其中羧基可以被酰胺化; X表示D-鸟氨酸 - 脯氨酸，脯氨酰-D-鸟氨酸，D-赖氨酰 - 脯氨酸残基等;条件是A1，A3，A4，A5， A6和A7是丙氨酸残基等，或X是瓜氨酸等）或其盐。
-
29.发明授权Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A 失效鉴定恶性疟原虫红细胞膜蛋白1（PfEMP1）的结构域，其介导对硫酸软骨素A的粘附公开(公告)号：US06855323B2
公开(公告)日：2005-02-15
申请号：US10087013
申请日：2002-02-21
申请人： Artur Scherf , Louis H. Miller , Benoit Gamain , Dror I. Baruch , Pierre Buffet , Christine Scheidig , Jurg Gysin , Bruno Pouvelle , Nobutaka Fujii , Joseph Smith
发明人： Artur Scherf , Louis H. Miller , Benoit Gamain , Dror I. Baruch , Pierre Buffet , Christine Scheidig , Jurg Gysin , Bruno Pouvelle , Nobutaka Fujii , Joseph Smith
IPC分类号： A61K38/00 , A61K39/00 , A61K48/00 , C07K14/445 , C12N15/30 , C12Q1/68 , G01N33/569 , A61K39/015 , A61K39/002 , C07K14/00
CPC分类号： C07K14/445 , A61K38/00 , A61K39/00 , A61K48/00 , A61K2039/505 , A61K2039/53 , C12Q1/6883 , C12Q2600/158 , G01N33/56905 , G01N2333/445 , Y02A50/412
摘要： The present invention relates to the discovery of a var gene and corresponding protein that modulates adhesion of parasitized red blood cells to chondroitin sulfate A. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.
摘要翻译： 本发明涉及一种调节寄生红细胞粘附到硫酸软骨素A上的var基因和相应蛋白质的发现。还公开了上述的新型生物工具，预防，治疗，诊断和使用方法。
-
公开(公告)号：US06545125B1
公开(公告)日：2003-04-08
申请号：US09554706
申请日：2000-05-18
申请人： Nobutaka Fujii
发明人： Nobutaka Fujii
IPC分类号： A61K3804
摘要： Compounds of the formula (1) or tautomers, stereoisomers or optical isomers thereof of the formula X—L—Y wherein X is paclitaxel or its derivative; L represents a linker having at least one functional group; and Y represents
摘要翻译： 式（1）的化合物或其互变异构体，立体异构体或其旋光异构体是紫杉醇或其衍生物; L表示具有至少一个官能团的连接体; 和Y代表
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.037 秒)
